Our top pick for
Sanofi is a drug manufacturers-general business based in the US. Sanofi shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi employs 100,409 staff and has a market cap (total outstanding shares value) of USD$121.2 billion.
|Latest market close||USD$50.27|
|52-week range||USD$36.3152 - USD$55|
|50-day moving average||USD$48.6697|
|200-day moving average||USD$50.2892|
|Wall St. target price||USD$64.83|
|Dividend yield||USD$1.7 (3.54%)|
|Earnings per share (TTM)||USD$1.94|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||4.62%|
|1 month (2020-12-18)||4.47%|
|3 months (2020-10-16)||50.27|
|6 months (2020-07-17)||-5.61%|
|1 year (2020-01-17)||-1.89%|
|2 years (2019-01-18)||21.19%|
|3 years (2018-01-18)||12.94%|
|5 years (2016-01-15)||30.20%|
Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Sanofi shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0129. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$25.7 billion|
|Return on assets TTM||4%|
|Return on equity TTM||0%|
|Market capitalisation||USD$121.2 billion|
TTM: trailing 12 months
There are currently 3.2 million Sanofi shares held short by investors – that's known as Sanofi's "short interest". This figure is 9.9% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting Sanofi shares can be evaluated.
Sanofi's "short interest ratio" (SIR) is the quantity of Sanofi shares currently shorted divided by the average quantity of Sanofi shares traded daily (recently around 1.6 million). Sanofi's SIR currently stands at 2.04. In other words for every 100,000 Sanofi shares traded daily on the market, roughly 2040 shares are currently held short.
However Sanofi's short interest can also be evaluated against the total number of Sanofi shares, or, against the total number of tradable Sanofi shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sanofi's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sanofi shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Sanofi shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sanofi.
Find out more about how you can short Sanofi stock.
Dividend payout ratio: 49.28% of net profits
Recently Sanofi has paid out, on average, around 49.28% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.54% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.54% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $1.7 per share.
While Sanofi's payout ratio might seem fairly standard, it's worth remembering that Sanofi may be investing much of the rest of its net profits in future growth.
Sanofi's most recent dividend payout was on 26 May 2020. The latest dividend was paid out to all shareholders who bought their shares by 30 April 2020 (the "ex-dividend date").
Sanofi's shares were split on a 5:1 basis on 30 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi shares which in turn could have impacted Sanofi's share price.
Over the last 12 months, Sanofi's shares have ranged in value from as little as $36.3152 up to $55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.3606. This would suggest that Sanofi's shares are less volatile than average (for this exchange).
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.